Cellectricon, a provider of advanced cell-based screening technologies, has launched its Discovery Services division. The new services offer phenotypic screening support to pharma/biotech companies and CROs, aimed at accelerating drug discovery and cell-based assay research into cytoskeletal disturbances, especially for chronic pain.
 
Cellectricon’s Discovery Services aim to shorten lead development times and reduce costs with expertise in assay development and screening. Cellectricon’s Discovery Services team provides interactive collaborative support for the entire services process, with frequent reports on assay performance, observations and
progress.
 
Dr. Paul Karila, head of Cellectricon’s Discovery Services, said, “Our Cellaxess Elektra discovery platform is ideal for compound profiling in excitable primary cells and native tissue using transfection and specific electric field stimulation (EFS). With our platform, we can help researchers identify phenotypic effects in highly relevant biological models early enough in a project’s lifecycle to add real value to the decision of whether to pursue or eliminate a compound, which translates to considerable cost savings in the drug development business.”